340B Drug Pricing Program
The full U.S. Court of Appeals for the District of Columbia Circuit denied AHA’s request to reconsider two decisions from this summer that upheld the Centers for Medicare & Medicaid Services’ cuts to payments for 340B drugs and for off-campus hospital outpatient clinic visits.
The full U.S. Court of Appeals for the District of Columbia Circuit Oct. 16 denied AHA’s request to reconsider two decisions from this summer that upheld the Centers for Medicare & Medicaid Services’ cuts to payments for 340B drugs and for off-campus hospital outpatient clinic visits.
AHA urges HHS to stop drug companies’ refusal to provide required 340B discounts
AHA follows up on our previous correspondence on the serious situation Eli Lilly, AstraZeneca and Sanofi are creating for the nation’s most vulnerable communities by refusing to comply with the requirements of the 340B program to sell to contract pharmacies at the discounts required by section 340B…
In comments on OPPS proposed rule, AHA urges HHS to immediately reverse 340B cuts
The AHA submitted comments on the Centers for Medicare & Medicaid Services’ outpatient prospective payment system and ambulatory surgical center payment system proposed rule for calendar year 2021.
AHA comments on the Centers for Medicare & Medicaid Services’ hospital outpatient prospective payment system and ambulatory surgical center payment system proposed rule for calendar year 2020.
Appeals Court Urged to Reconsider Decision Upholding 340B Hospital Payment Cuts
New Analysis Shows 340B Tax-exempt Hospitals Provided More Than $64B in Benefits to Communities
AHA seeks rehearing of U.S. appeals court decision on cuts to 340B hospitals